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Hodgkin’s lymphoma is one of the best suited malignancies for
targeted immunotherapy for the following reasons: (1) Hodgkin 
Reed-Sternberg (H–RS) cells have surface markers such as CD25
and CD30, which are present only on a minority of normal lymphoid
cells; (2) The number of malignant cells that needs to be killed is
small since the majority of cells in Hodgkin’s lymphoma are non-
malignant reactive cells; (3) Hodgkin tumours are usually well-
vascularized, suggesting that access of an immunotherapeutic agent
like an immunotoxin (IT) to the target cells should be easier than in
solid tumours; (4) Although Hodgkin’s lymphoma is known to
respond well to chemotherapy, residual tumour cells remaining after
first-line treatment have been demonstrated to correlate with the
probability of a later relapse. As the selective elimination of residual
H–RS cells might enhance the number of patients being cured, it
seems feasible to eradicate bulky disease by conventional therapy
first and then to administer immunotoxins to kill residual H–RS cells.
One problem associated with the use of immunotoxins is the
heterogeneity of antigen expression on tumour cells and therefore
the selection of antigen-negative tumour cells (Engert et al, 1990;
Vitetta et al, 1993). This problem can be circumvented by the
application of immunotoxin cocktails, i.e. mixtures of immuno-
toxins against different antigens on the same target cell.
Immunotoxin cocktails have demonstrated better effects as
compared to the use of single immunotoxins in animal lymphoma
models (Ghetie et al, 1992). In addition, a cocktail consisting of
immunotoxins against different antigens has given superior results
against Hodgkin’s lymphoma, both in vitro and in vivo (Engert
et al, 1995). Thus, our group has developed a variety of immuno-
toxins for possible clinical use in Hodgkin’s lymphoma, like anti-
CD25, anti-CD30 and anti-interleukin (IL)-9 receptor immuno-
toxins (Engert et al, 1990, 1997; Klimka et al, 1996).
One of the most promising candidate target antigens for
immunotherapeutics against Hodgkin’s disease (HD) is CD30.
The CD30 antigen was originally discovered on cultured H–RS
cells using the monoclonal antibody (mAb) Ki-1 (Schwab et al,
1982). Expression screening permitted the cloning of the gene that
encodes for the CD30 receptor molecule (Dürkop et al, 1992),
which is located on chromosome 1p36. Subsequently, the naturally
occurring CD30 ligand was identified and cloned (Gruss et al,
1995). The CD30/CD30 ligand system can trigger cytolytic cell
death in malignant lymphoma cell lines and has been demon-
strated to induce proliferation and cytokine production in T-cells
or neutrophils (Wiley et al, 1996). Since CD30 is present in high
copy numbers on malignant lymphoma cells and has a very limited
distribution on normal cells, mAbs against CD30 have been
explored as vehicles for cytostatic drugs (Sahin et al, 1990) or
plant toxins (Terenzi et al, 1996). Immunotoxins constructed with
anti-CD30 mAbs have demonstrated specificity and potent anti-
tumour activity against Hodgkin’s lymphoma cells in vitro and in
mouse models (Engert et al, 1990; Schnell et al, 1995). A clinical
trial has been reported using an immunotoxin constructed by
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SummaryThe human CD30 receptor is highly overexpressed on the surface of Hodgkin Reed-Sternberg cells and has been shown to
be an excellent target for selective immunotherapy using monoclonal antibody-based agents such as immunotoxins. To construct a new
recombinant immunotoxin for possible clinical use in patients with Hodgkin’s lymphoma, we have chosen the murine anti-CD30 hybridoma
Ki-4 to generate a high-affinity Ki-4 single-chain variable fragment (scFv). Hybridoma V-genes were polymerase chain reaction-amplified,
assembled, cloned and expressed as a mini-library for display on filamentous phage. Functional Ki-4 scFv were obtained by selection of
binding phage on the Hodgkin lymphoma-derived, CD30-expressing cell line L540Cy. The selected recombinant Ki-4 scFv was shown to
specifically bind to an overlapping epitope on the CD30 antigen with binding kinetics similar to those of the original antibody. The Ki-4 scFv
was subsequently fused to a deletion mutant of Pseudomonas exotoxin A (ETA´). The resulting immunotoxin Ki-4(scFv)-ETA´ specifically
binds to CD30+ L540Cy cells and inhibits the protein synthesis by 50% at a concentration (IC50) of 43pM. This recombinant immunotoxin is a
promising candidate for further clinical evaluation in patients with Hodgkin’s lymphoma or other CD30+ malignancies.
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chemically linking the anti-CD30 mAb BerH2 to Saporin-6
(Pasqualucci et al, 1995). Twelve patients with advanced refrac-
tory Hodgkin’s lymphoma were enrolled and five patients exhib-
ited a rapid reduction in tumour masses, underlining the validity of
CD30 as a target antigen in HD.
The problems identified in these and other clinical trials with
immunotoxins are the development of antibodies against the
immunotoxins neutralizing their effects (Grossbard et al, 1993;
Vitetta et al, 1993), liver toxicity and vascular leak syndrome. In
addition, there are difficulties in producing large quantities of
chemically linked immunotoxins for randomized clinical trials.
These problems might, at least in part, be overcome by using
recombinant DNA technology which makes the construction of
less immunogenic and smaller immunotoxins feasible, and more
easily permits the production of immunotoxins in large quantities.
It is also believed that penetration into tumours should be better
for small proteins than large conjugates. Recombinant immuno-
toxins can be engineered by fusing only the small antigen-binding
part of a whole antibody to bacterial or plant toxin genes, lacking
their binding domains (reviewed in Kreitman and Pastan, 1994).
In this paper, we report the successful cloning of the variable
genes of the recently evaluated anti-CD30 mAb Ki-4, which has
been shown to inhibit the shedding of the extracellular part of the
CD30 molecule (Horn-Lohrens et al, 1995). A chemically linked
ricin A-chain immunotoxin (Ki-4-SMPT-dgA) constructed with
Ki-4 mAb exhibited powerful specific cytotoxicity (IC50 of 40 pM)
against CD30+ tumour cells in vitro and cured 60% of severe
combined immune deficient (SCID) mice treated with a single
injection of 8 mg (Schnell et al, 1995). The phage display tech-
nology made it possible to get access to a specific, high-affinity
Ki-4 single-chain variable fragment (scFv) which was further
genetically fused to a modified Pseudomonas exotoxin A gene
(ETA´). We demonstrate that the new recombinant immunotoxin
constructed with the selected scFv, Ki-4(scFv)-ETA´, is specific
and highly effective in destroying a CD30+ Hodgkin-derived cell
line. This scFv-based immunotoxin is a good candidate on its own,
or in combination with other immunotoxins, for immunotherapy
of Hodgkin’s disease.
MATERIALS AND METHODS
Cell lines
The Hodgkin-derived cell line L540Cy, the Burkitt lymphoma cell
line BL38, and the hybridoma cell lines Ki-3 and Ki-4 (Horn-
Lohrens et al, 1995) were maintained in RPMI-1640 medium
(Gibco) supplemented with 10% (v/v) fetal calf serum (FCS),
100 mg ml–1 streptomycin, 200 units ml–1 penicillin and 2 mM
L-glutamine. Transfected baby hamster kidney (BHK)-21 cells
secreting a construct of the extracellular domain of the human
CD30 receptor fused to the hinge, CH2 and CH3 domain of human
IgG1 (sCD30-Fc) were kindly provided by H-J Gruss (Ulm,
Germany) and maintained in RPMI-1640 medium supplemented
with 10% (v/v) IgG-free FCS (c.c. pro GmbH) and 1 mg ml–1
gentamycin (PAA). All cells were cultured at 37°C in a 5% carbon
dioxide atmosphere.
Bacterial strains and plasmids
Escherichia coli TG-1 (K12 D(lac-pro), supE, thi, hsdD5/F´traD36,
proA+B+, lacIq, lacZDM15) and E. coli HB2151 (K12 D(lac-pro),
ara, nalr, thi/F´, proA+B+, lacIq, lacZDM15) were purchased from
Pharmacia. The phagemid vector pCANTAB6 (McCafferty et al,
1994) is derived from pHEN1 (Hoogenboom et al, 1991), carrying
an additional His6-tag for immobilized metal-ion affinity chro-
matography (IMAC) purification and a myc-tag for detection by
anti-myc-tag antibody 9E10 (Munro et al, 1986). It is used for N-
terminal fusion of SfiI/NotI-scFv fragments to the minor coat protein
p3 of filamentous phage M13 (Figure 1). The plasmid pBM1.1
(Matthey et al, 1999) is derived from the pET27b vector (Novagen)
and is used for N-terminal fusion of scFvs to a modified deletion
mutant of Pseudomonas aeruginosa exotoxin A (Wels et al, 1992),
detectable by anti-ETA mAb TC-1 (kindly provided by DR
Galloway, Ohio, USA).
Cloning of the murine Ki-4 scFv
Total cellular RNA from 107 cells of the Ki-4 hybridoma cell line
was isolated using the RNazolTM solution (Biotecx) as described
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Figure 1 Cloning schedule of Ki-4(scFv)-ETA´. Phagemid vector
pCANTAB6 contains a His6-tag (H) for immobilized metal ion chromatography
(IMAC) purification of the scFv and a c-myc-tag (myc) for its detection using
an anti-myc antibody. The g3L sequence encodes for a signal peptide
guiding the native protein into the periplasm and gene 3 encodes the phage
coat protein p31216 A Klimka et al
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by the manufacturer. cDNA was synthesized using 5 mg of freshly
prepared RNA and 10 ml random hexamer primers (10 mM) of the
RiboClone cDNA Synthesis Systems kit (Promega) in a 50 ml
reaction mix. VH and VL genes were amplified from 5 ml of
cDNA using 20 pmol of each primer VH1BACK/VH1FOR-2 and
VKBACKmix/VKFOR4mix (Roovers et al, 1998) and assembled
with a linker sequence (Gly4Ser)3 according to Marks et al (1991)
(Figure 1). Assembly products were gel-purified and phenol-
extracted. Purified fragments were cloned into the phagemid
vector pCANTAB6 using the restriction sites SfiI/NotI. The liga-
tion mix was purified by phenol extraction, precipitated with
ethanol, and dissolved in 10 ml water. The DNA solution was
transfected into 50 ml E. coli TG-1 by electroporation as described
elsewhere (Dower et al, 1988). The cells were grown for 1 h in
2 ´ TY medium at 37°C before plating on 2 ´ TY agar medium
containing 100 mg ampicillin ml–1 and 2% (w/v) glucose (2 ´ TY-
Amp-Glu).
Selection of phage particles on the Hodgkin cell line
L540Cy
A repertoire of transformed bacteria (approximately 105 clones)
containing scFv polymerase chain reaction (PCR) products ligated
into pCANTAB6 was rescued with helper phage M13K07 as
described (Marks et al, 1991). Five times 105 L540Cy cells were
incubated with 1 ml of 1 ´ 1013 colony forming units (cfu) per ml
phage in 2% (w/v) MPBS (2% Marvel – skimmed milk powder –
in PBS) for 1 h at room temperature (RT) on a rotating turntable.
After washing the cells ten times with 5 ml 2% MPBS and two
times with 5 ml PBS by spinning (300 g, 3 min, RT) and resus-
pending respectively, binding phage were eluted using 1.5 ml
50 mM hydrochloric acid for 10 min on a turntable. Eluted material
was immediately neutralized by adding 0.5 ml 1 M Tris–HCl
(pH 7.5) and remaining cell debris was spun down (300 g, 5 min,
RT). Phage-containing supernatant was mixed with 3 ml 2 ´
TY-Glu medium and used to transfect 5 ml logarithmically
growing  E. coli TG-1 cells for 30 min at 37°C before plating them
on 2 ´ TY-Amp-Glu agar medium.
Whole cell ELISA
A total of 1 ´ 107 L540Cy cells were resuspended in 10 ml PBS
containing 2% (w/v) bovine serum albumin (BSA) (PBSA 2%).
Then, 100 ml of cellular suspension were filled in each well of a V-
bottom microtitre plate (Greiner) and centrifuged (500 g, 3 min,
RT). Supernatant was removed by flicking the plate. Cell pellets
were resuspended in 150 ml PBSA 2% and incubated for 1 h at
RT. Cells were centrifuged (500 g, 3 min, RT), supernatant was
discarded, and cells were resuspended in 150 ml PBS containing
0.1% (w/v) BSA (PBSA 0.1%). This washing step was repeated
Figure 2 Sequence of Ki-4 scFv with deduced amino acids. Nucleotides derived from primers are underlined. The complementarity determining regions (CDR)
and the (Gly4Ser)3 linker between the heavy and light chain are indicatedRecombinant anti-CD30 immunotoxin 1217
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once and cells were resuspended in 50 ml of soluble fragment-
containing supernatants of induced bacterial clones according to
Marks et al (1991). After 1 h incubation the L540Cy cells were
washed three times in 150 ml PBSA 0.1% and subsequently incu-
bated for 1 h in 50 ml of one-fifth-diluted hybridoma supernatant
of the anti-myc-tag antibody 9E10. Cells were washed three times
in 150 ml PBSA 0.1% and resuspended in 50 ml of a 1/5000-
diluted rat anti-mouse IgG peroxidase-conjugated antibody
(Dianova). After 30 min incubation at RT, cells were washed four
times in 150 ml PBS, transferred to a new V-bottom 96-well plate
and incubated with 50 ml peroxidase-substrate. After incubation
for approximately 15 min, the reaction was stopped by addition of
50 ml H2SO4 (2 N) and cells were centrifuged again. Extinction at
490 nm was measured with an enzyme-linked immunosorbent
assay (ELISA) reader (MWG) after transferring the supernatants
to a flat-bottom microtitre plate. Clones were considered positive
for CD30-binding if the OD490 was at least three times higher than
the background.
Cell-binding activity of Ki-4 scFv
Five times 105 L540Cy cells were washed in 2% (w/v) MPBS
containing 0.05% (w/v) sodium azide (2% MPBS/N3–), and then
incubated for 1 h at 4°C with approximately 1010 cfu of phage
displaying Ki-4 scFv and unpurified supernatant from hybridomas
secreting mAb Ki-3 or mAb Ki-4 respectively. Bound phage were
detected with a sheep anti-fd serum (Pharmacia; 0.02% (v/v) in
2% MPBS/N3–) and fluorescein isothiocyanate (FITC)-labelled
rabbit-anti-sheep IgG (Dianova; 2% (v/v) in PBS/N3–).
Appropriate amounts of stained cells were brought onto slides by
cytocentrifugation (300 g, 10 min), fixed using a 1/9-DABCO-
(20% 1,4 diazabicyclo[2.2.2.]octane (Sigma) in 0.2 M Tris–HCl,
pH 8, 0.02% NaN3–) DAPI-(0.5 mg 4,6-diamidino-2-phenylindole
(Sigma) in 100% glycerol) solution and subsequently analysed on
a fluorescence microscope (Leica).
Purification of Ki-4 scFv
E. coli HB2151, harbouring the Ki-4 scFv in pCANTAB6, was
used to inoculate 250 ml of 2 ´ TY-Amp-Glu. The culture was
grown at 37°C to an OD600 of 0.9, subsequently centrifuged and
resuspended in 50 ml 2 ´ TY-Amp with 1 mM isopropyl-b-
D-galactopyranoside (IPTG) for induction of soluble scFv expres-
sion. After 5 h of induction, the cells were placed on ice for
20 min, pelleted and resuspended in 5 ml ice cold PBS with 1 M
sodium chloride and 1 mM EDTA in total. After incubation for 30
min on ice, the suspension was centrifuged (3000 g, 10 min, RT)
to remove bacteria and the resulting periplasmic fraction was
subsequently centrifuged for 10 min at 25 000 g to remove cell
debris. The scFvs were further purified by IMAC using 2 ml
Ni-NTA resin (Qiagen) according to the manufacturer’s instruc-
tions. Eluted protein was thoroughly dialysed against PBS and
checked on sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and by immunoblotting. The final con-
centration was determined from a scanned Coomassie-stained
SDS-PAGE using the Molecular Analyst software (Bio-Rad).
Kinetic measurement using SPR in a BIAcore
Binding kinetics of the Ki-4 mAb and the Ki-4 scFv were determined
performing surface plasmon resonance (SPR) in a BIAcore 2000
(Pharmacia) using recombinant, human sCD30-Fc protein, which
was purified from supernatant of stable transfected BHK cells on an
anti-human IgG resin (Sigma) according to the manufacturer’s
instructions. sCD30-Fc protein was covalently coupled to a CM-5
sensorchip (Pharmacia) via free amide chemistry, resulting in a
surface of 450 resonance units (RU). This ‘low density’ CD30
surface was saturated with antibody or antibody fragment using
multiple injections of protein and a flow rate of 20 ml min–1.
Dissociation rates were then determined by curve fitting from the
resulting sensorgrams using the BIAevaluation software (Pharmacia).
A
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Figure 3 Competitive immunofluorescence staining of L540Cy cells with
Ki-4 scFv displayed on phage. Cells were incubated with (A) phage
displaying no recombinant protein, (B) phage displaying Ki-4 scFv on their
surface and supernatant of Ki-3 hybridoma for competition, (C) phage
displaying Ki-4 scFv and supernatant of Ki-4 hybridoma for competition.
Binding of phage was detected with sheep anti-fd serum and FITC-labelled
rabbit-anti-sheep IgG. Cells were centrifuged on slides and fixed with
DABCO/DAPI in glycerol, giving a blue nuclear staining. Scale bar: 45 mm1218 A Klimka et al
British Journal of Cancer (1999) 80(8), 1214–1222 © 1999 Cancer Research Campaign 
Construction and purification of the recombinant anti-
CD30 immunotoxin Ki-4(scFv)-ETA´
Ki-4 (scFv) gene was released from phagemid vector pCANTAB6
by SfiI/NotI digestion and inserted into SfiI/NotI digested expres-
sion vector pBM1.1 containing a modified Pseudomonas exotoxin
A (ETA´)-gene (Wels et al, 1992). The resulting pBM1.1-Ki-
4(scFv)-ETA´ plasmid was transformed into E. coli BL21 (DE3)
(Novagen). Recombinant Ki-4(scFv)-ETA´ was purified from
inclusion bodies and refolded with the help of 6 M guanidinium
hydrochloride according to a previously described protocol
(Plaksin et al, 1996). Purification was performed by ion-exchange
chromatography using a mono-Q column (Pharmacia). Protein
concentration was determined by SDS-PAGE and Coomassie
staining, using BSA standards and densitometrical analysis with
Molecular Analyst software (Bio-Rad).
Binding activity and cytotoxicity of Ki-4(scFv)-ETA´
Binding specificity of Ki-4(scFv)-ETA´ was demonstrated by
means of FACS analysis using a FACScan (Becton Dickinson).
Target cells were washed in 2% (w/v) MPBS containing 0.05%
(w/v) sodium azide (2% MPBS/N3–) and incubated with 50 ml of
Ki-4(scFv)-ETA´ (10 mg ml–1) in 2% MPBS/N3– for 1 h at 4°C.
Bound Ki-4(scFv)-ETA´ was detected with the anti-ETA mAb TC-
1 (20% (v/v) hybridoma supernatant in 2% MPBS/N3–) and FITC-
conjugated goat-anti-mouse IgG (Becton Dickinson; 2% (v/v) in
PBS/N3–).
The effect of Ki-4(scFv)-ETA´ on the protein synthesis of target
cell lines was determined by measurement of [3H]-leucine incor-
poration as described (Barth et al, 1998). A competitive protein
synthesis inhibition assay was performed by adding 10 mg ml–1
purified Ki-4 mAb or 10 mg ml–1 OKT3 moab (Cilac) as a control
to a dilution series of Ki-4(scFv)-ETA´.
RESULTS
Cloning of V-genes and selection of the Ki-4 scFv
After extraction of total RNA from the hybridoma cell line Ki-4,
the variable domains of heavy (VH) and light (VL) chain
immunoglobulin genes were amplified by means of reverse tran-
scription (RT)-PCR using an improved set of oligonucleotides
(Roovers et al, 1998) and assembled by Splice Overlap Extension
(SOE-) PCR (Marks et al, 1991) with a (Gly4Ser)3 linker. The
resulting single-chain variable fragment (scFv) was cloned into
phagmid vector pCANTAB6 for expression as a fusion product
with the bacteriophage coat protein p3 (Figure 1) or as a soluble
scFv fragment, depending on the expression conditions (Marks et
al, 1991). The first screening of soluble scFv fragments produced
by 94 different bacterial clones in a whole cell ELISA using the
CD30-positive Hodgkin-derived cell line L540Cy revealed no
binders. To retrieve a functional scFv from the hybridoma cell line
Ki-4, phage particles were prepared from approximately 105
bacterial clones containing scFv cloning products. Two successive
rounds of selection on L540Cy cells were performed to enrich the
population to finally 95% L540Cy binding scFv clones determined
in a whole cell ELISA (data not shown).
V gene sequences of Ki-4 scFv
The DNA sequences of VH and VL chain from two selected
murine Ki-4 scFv were determined using a semi-automated
ALFexpress sequencer (Pharmacia) and fluorescence-labelled
primers, annealing downstream of the scFv cassette in the gene 3
of pCANTAB6 or upstream of the scFv cassette in the
pCANTAB6 backbone. The determined nucleic acid sequence and
its deduced amino acid sequence are depicted in Figure 2. The
nucleic acid sequences of the V regions were compared to the
Kabat database of murine V-genes (http://immuno.bme.nwu.edu/
famgroup.html) to determine the V gene family. The VH gene
segment belongs to the Kabat VII and the VL gene to the Kabat
XXI family. The scFv sequence was submitted to GenBank (acces-
sion number AF002242).
Binding properties of Ki-4 scFv
Binding of Ki-4 scFv to the L540Cy cells was demonstrated
by means of immunofluorescence staining (Figure 3). To verify
binding specificity of the Ki-4 scFv to the CD30-epitope recog-
nized by the Ki-4 mAb, competition experiments were performed.
As shown in Figure 3C, a reduction in green immunofluorescence
staining is visible if Ki-4 scFv displayed on phage was simultane-
ously incubated with the parental Ki-4 mAb. In contrast, when the
Ki-3 mAb was used, which recognizes a different, non-overlap-
AB
68 kDA —
43 kDA —
25 kDA —
M123 M123
Figure 4 Purification of Ki-4 scFv by IMAC. SDS-PAGE gel was stained with Coomassie (A) and a Western blot (B) was performed, using a mouse anti-myc-
tag mAb, and anti-mouse mAb conjugated with streptavidin-alkaline phosphatase, visualized by phosphatase substrate. Lane M, prestained molecular weight
marker; lane 1, periplasmic extraction; lane 2; flow through of Ni-NTA resin; lane 3, eluate of Ni-NTA resinRecombinant anti-CD30 immunotoxin 1219
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ping epitope on the CD30 antigen, no reduction in fluorescence
intensity was observed (Figure 3B). A control experiment with
phage displaying no scFv on their surface exhibits only the blue
nuclear background staining of the L540Cy cells, due to treatment
of the cells with DAPCO/DAPI (Figure 3A). The Ki-4 scFv-gene
in pCANTAB6 was subsequently introduced in E. coli non-
suppressor strain HB2151, which does not translate the amber-stop
codon between the scFv- and the p3-gene, and therefore solely
expresses soluble scFv. After induction with IPTG, His-tagged
Ki-4 scFv produced from HB2151 cells was purified from
periplasmic fraction using a Ni-chelate resin. The Ki-4 scFv was
recovered in a highly purified form (purity > 90%; Figure 4A) and
identified by Western blot-analysis as a 27-kDa band (Figure 4B).
The typical yield of purified scFv was approximately 200 mg l–1
bacterial culture.
One of the most important characteristics of antibodies to be
used in tumour targeting is the rate with which they detach from
bound antigen on the cell, determined in part by the off-rate of the
molecule (Adams et al, 1993). We compared the off-rates of Ki-4
whole antibody and Ki-4 scFv performing SPR in a BIAcore 2000
(Figure 5 and Table 1) with purified sCD30-Fc protein. As can be
seen in Table 1, the off-rates differ by a factor of 1.5 only. The
predicted half-life of the antibody–antigen complex was calculated
as t1/2 = ln2/koff, resulting in 96 min for the whole antibody and
64 min for the antibody fragment.
Construction and purification of the recombinant
Ki-4(scFv)-ETA´ immunotoxin
After recloning of the Ki-4 scFv gene into the expression vector
pBM1.1, which encodes a modified Pseudomonas exotoxin A gene,
the fusion toxin Ki-4(scFv)-ETA´ was expressed in E. coli BL21
(DE3). The recombinant immunotoxin could be extracted from
inclusion bodies, de- and renaturated and finally purified to a high
degree (purity > 90%; Figure 6) by ion exchange chromatography.
Specific binding and cytotoxicity of Ki-4(scFv)-ETA´
Binding activity of purified Ki-4(scFv)-ETA´ towards the target
cell line L540Cy and the CD30-negative cell line BL38 as a
control, was investigated by FACS analysis. Ki-4(scFv)-ETA´
binds to L540Cy cells (Figure 7B) but not to BL38 cells (Figure
7A). Specific cytotoxicity of the Ki-4(scFv)-ETA´ construct was
demonstrated in a protein inhibition assay (Figure 8) for the
CD30+ cell line L540Cy, showing an IC50 of 43 pM. There was no
unspecific toxicity against the CD30– cell line BL38. In addition,
the cytotoxicity against CD30+ cells was specifically abrogated by
an excess (10 mg ml–1) of purified Ki-4 mAb but not by addition of
anti-CD3 antibody OKT3 (10 mg ml–1).
DISCUSSION
In this paper, we report a new recombinant molecule (Ki-4 scFv)
selected by phage display that binds to the CD30 antigen with high
affinity. We subsequently used the Ki-4 scFv to construct a new
anti-CD30 single-chain immunotoxin (Ki-4(scFv)-ETA´) by
fusing the scFv to a modified Pseudomonas exotoxin A variant
(ETA´). The major findings emerging from the present study are:
(i) phage display technology allowed the identification of a high-
affinity anti-CD30 Ki-4 scFv by direct selection of a hybridoma-
derived phage antibody-repertoire on cells carrying the CD30
antigen; (ii) the Ki-4(scFv)-ETA´ immunotoxin shows potent
and specific toxicity against the CD30+ malignant Hodgkin’s
lymphoma cell line L540Cy (IC50 of 43 pM).
The in vitro potency of the new single-chain immunotoxin Ki-
4(scFv)-ETA´, described in the present paper, is similar to the
parental IgG-based Ki-4-SMPT-dgA (IC50 of 40 pM). Investigating
the anti-CD30 antibody–antigen interaction using surface plasmon
Table 1 Kinetic data of Ki-4 whole antibody and Ki-4 scFv
koff koff t1/2
Antibody (10–4 s–1) ± SE (10–4 s–1) ± SE (=In2/koff)
(monovalent) (bivalent)
Ki-4 mAb – 1.2 ± 0.2 96 min
Ki-4 scFv 1.8 ± 0.5 – 64 min
The kinetic data were evaluated by surface plasmon resonance
measurements in a BIAcore 2000 using recombinant, human sCD30-Fc
protein as antigen. The off-rates were determined from the sensorgrams in
Figure 5. koff, off-rate; t1/2, half-life of antibody–antigen complex.
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Figure 5 Kinetic measurement using the BIAcore. Sensorgrams showing
surface plasmon resonance (SPR) measurements of Ki-4 mAb (A) and Ki-4
scFv (B) towards covalently coupled sCD30-Fc protein. Off-rates were
determined by curve fitting on the time intervals 800–810 s (A) and
3850–3860 s (B) respectively1220 A Klimka et al
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resonance (SPR) in a BIAcore showed that Ki-4 mAb has a similar
off-rate compared to Ki-4 scFv (Table 1), indicating that both
immunotoxins most likely have similar binding affinities for
CD30. The fact that the monovalent Ki-4(scFv)-ETA´ is highly
specific and cytotoxic, indicates that cross-linking of the target
antigen CD30 does not seem to be necessary for the immunotoxin
to be internalized. Endocytosis of the CD30-receptor is more
likely a regular process, probably in connection with a continuous
recycling of the CD30 receptor. Nevertheless, the cytotoxic effect
of the recombinant, monovalent immunotoxin may be further
increased by creating a bivalent single-chain Fv fused to the toxin,
which would possibly benefit from avid binding and enhanced
internalization efficacy.
Surprisingly, no functional recombinant anti-CD30 immunotoxin
has yet been published, although the construction of recombinant
antibody fragments against cell surface markers and immunotoxins
against a variety of malignant cells has been reported (Kreitman and
Pastan, 1994). Reasons for the difficulty in obtaining functional,
recombinant scFv by cloning V-genes from hybridomas are errors
introduced during PCR amplification, alterations in the genes
introduced by the primers used, and cloning artefacts including dele-
tions, recombinations, insertions or frameshifts. In addition, the
presence of non-functional pseudogenes or aberrantly expressed
V gene transcripts of the hybridoma fusion partner can critically
reduce the proportion of functional scFv (Bradbury et al, 1995).
Indeed, a screening of 94 clones with about 90% containing fully
scFv inserts, revealed no functional scFv. Therefore we performed
two successive rounds of phage selection using a mini-repertoire of
105 scFv clones to enrich a binding Ki-4 scFv clone to 95%. Rather
than selecting the phage repertoire on purified CD30 antigen, we
used whole cells with intact native CD30. We retrieved functional
scFv fragments, which could not be detected in the starting reper-
toire, by simple cycles of cell panning, reamplification and phage
rescue. Major advantages of this approach is that no well-character-
ized, purified cell surface antigen is needed and that the resulting
antibody recognizes the naturally folded protein. We have recently
extended this method of cell panning with phage scFv libraries, to
derive a human antibody to CD30, in which the murine Ki-4 scFv
was converted into a fully human version by ‘guided’ cell selection
(manuscript in preparation).
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Figure 6 Purification of Ki-4(scFv)-ETA´. The SDS-PAGE analysis was performed loading unpurified protein solution (lane 1), eluate of mono-Q-purification
(lane 2) and prestained molecular weight marker (lane M). The gel was stained with Coomassie (A) and a Western blot was subsequently performed using an
anti-ETA mouse IgG, anti-mouse mAb conjugated with streptavidin–alkaline phosphatase and phosphatase substrate to detect the recombinant Ki-4(scFv)-ETA´
R
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
Log fluorescence intensity
AB
1
0
0
5
0
0
1
0
0
5
0
0
100 101 102 103 104 100 101 102 103 104
Figure 7 Binding of Ki-4(scFv)-ETA´ to CD30-negative cell line BL38 (A) and CD30-positive Hodgkin-derived cell line L540Cy (B). Cells were stained with Ki-
4(scFv)-ETA´, anti-ETA-mouse IgG (TC-1) and FITC-conjugated anti-mouse IgG (white curves) or as negative controls with PBS instead of Ki-4(scFv)-ETA´
(black curves). Histograms represent logarithms of FITC-fluorescence on flow cytometerRecombinant anti-CD30 immunotoxin 1221
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There have been very few reports on the use of phage display
to isolate single-chain variable domains for the construction
of recombinant immunotoxins. Lorimer et al produced a
Pseudomonas exotoxin-based immunotoxin by fusing a scFv
specific for EGFRvIII selected from a phage display library
(Lorimer et al, 1996). Their construct also showed specific toxicity
against transfected malignant glioblastoma cells (IC50 of 110–
160 pM). Our new Ki-4(scFv)-ETA´ immunotoxin matches the
anti-EGFRvIII construct, in terms of specific toxicity (IC50 of
43 pM). Thus, the phage display technology seems to make the
isolation of specific binding moieties for the construction of
highly potent recombinant immunotoxins feasible.
In summary, the newly constructed recombinant anti-CD30
immunotoxin Ki-4(scFv)-ETA´ is highly effective and specific
against CD30+ H-RS cells and is therefore a good candidate, either
on its own or in combination with other immunotoxins for clinical
evaluation in patients with CD30+ lymphoma.
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were incubated with a tenfold dilution series of Ki-4(scFv)-ETA´. L540Cy cells
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concentrations of the recombinant IT. The results are expressed as the
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